BMY Q4 2022 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$124B

Q4 2022 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$11.4B-4.8% YoY

Gross Profit

$6.5B56.9% margin

Operating Income

$1.7B15.0% margin

Net Income

$2.0B17.7% margin

EPS (Diluted)

$0.95

QoQ Revenue Growth

+1.7%

Cash Flow

Operating Cash Flow

$3.3B

Free Cash Flow

$3.0B

Stock-Based Comp.

$119M

Balance Sheet

Total Assets

$96.8B

Total Liabilities

$65.7B

Stockholders' Equity

$31.1B

Cash & Equivalents

$9.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11.4B	$12.0B	-4.8%
Gross Profit	$6.5B	$7.2B	-9.8%
Operating Income	$1.7B	$2.2B	-23.3%
Net Income	$2.0B	$2.4B	-14.8%

Revenue Segments

Eliquis

$2.7B24%

Revlimid

$2.3B20%

Opdivo

$2.2B20%

Orencia

$913M8%

Pomalyst/Imnovid

$877M8%

Sprycel

$578M5%

Yervoy

$568M5%

Mature Products And All Other

$411M4%

Reblozyl

$199M2%

Abraxane

$179M2%

Abecma

$125M1%

Opdualag

$104M1%

Zeposia

$79M1%

Breyanzi

$55M0%

Camzyos

$16M0%

Sotyktu

$7M0%

Geographic Segments

UNITED STATES

$7.9B69%

Europe

$3.3B29%

Other Region

$200M2%